Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ When Administered in Sri Lankan Infants Aged at Least 6 Weeks at the Time of First Vaccination.

NCT00779779 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00779779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00779779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ When Administered in Sri Lankan Infants Aged at Least 6 Weeks at the Time of First Vaccination.
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
November 22, 2008
Completion date
August 26, 2009
Enrollment
522 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infections, rotavirus